How Forteo and Prolia Work to Build Bone
Forteo (teriparatide) is a synthetic parathyroid hormone fragment given daily by injection that stimulates osteoblasts to form new bone, increasing bone mineral density (BMD) primarily in the spine and hip.[1] Prolia (denosumab) is a RANKL inhibitor given every six months by injection that slows osteoclast activity to reduce bone resorption, preserving existing bone and modestly increasing BMD.[1][2]
Direct Comparison on Bone Building Effectiveness
Forteo generally builds more bone than Prolia in clinical trials. In head-to-head data and meta-analyses, Forteo increases lumbar spine BMD by 9-13% over 18-24 months, compared to 5-8% with Prolia.[3][4] Hip BMD gains are similar (3-5% for both), but Forteo shows greater trabecular bone formation on biopsies.[3] Neither is universally "better"—Forteo excels at anabolic rebuilding for severe cases, while Prolia is stronger for resorption-heavy osteoporosis.[2]
Who Gets Better Results from Forteo Over Prolia?
Forteo outperforms Prolia in high-risk patients with recent fractures or very low BMD (T-scores below -3.0), where anabolic effects reduce vertebral fracture risk by 65% versus 68% for Prolia non-vertebrally.[4][5] Women under 65 or those intolerant to bisphosphonates often respond better to Forteo's bone-forming action.[1] Prolia edges out in convenience and non-vertebral fracture prevention for broader postmenopausal use.[2]
Treatment Duration and Sequencing Rules
Forteo is limited to 2 years lifetime due to osteosarcoma risk in animal studies; it's often followed by an antiresorptive like Prolia to maintain gains.[1][6] Prolia can continue indefinitely (with monitoring for rebound fractures upon stopping).[2] Sequential Forteo then Prolia builds more bone long-term than Prolia alone.[4]
Key Risks and Side Effects Comparison
Forteo carries a black-box warning for osteosarcoma (rare in humans) and risks hypercalcemia; common issues include leg cramps and dizziness.[1] Prolia causes more hypocalcemia, jaw osteonecrosis (1/10,000-1/1000), and atypical femur fractures with long-term use.[2] Forteo suits shorter-term aggressive building; Prolia fits maintenance but needs careful discontinuation.[6]
Cost and Access Factors
Annual cost is ~$25,000-$30,000 for both without insurance; Forteo's daily injections raise adherence barriers.[7] Patents for Forteo expired in 2019 in the US, allowing generics abroad, while Prolia's exclusivity runs until 2025 (biosimilars emerging).[8] DrugPatentWatch.com lists Prolia's key patent (US 7,364,736) expiring October 2025.
[1] Forteo prescribing information, Eli Lilly.
[2] Prolia prescribing information, Amgen.
[3] NEJM 2001;345:1434-41 (Forteo trial); Lancet 2010;376:599-608 (Prolia).
[4] JBMR 2017;32:889-97 (meta-analysis).
[5] Lancet 2009;373:1250-9.
[6] JBMR 2014;29:1243-9 (sequencing).
[7] GoodRx pricing data, 2023.
[8] DrugPatentWatch.com.